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asil S. Lewis, MD, David A. Halon, MB, CHB
aifa, Israel
he new millennium has ushered in a new era in our
nderstanding and treatment of atherosclerotic vascular dis-
ase. Using new imaging technologies, we have windows into
he vasculature: intravascular ultrasound (IVUS) and related
echnologies (virtual histology [VH], optical coherence tomog-
aphy), carotid intima-media thickness, calcium scoring, and
oninvasive angiography using multislice computed tomogra-
hy (CT), and magnetic resonance imaging. Regarding treat-
ent and prevention, we have clear evidence that lowering
ow-density lipoprotein cholesterol (LDL-C) and modulating
igh-density lipoprotein cholesterol (HDL-C) may limit the
rogression of vascular disease and improve clinical outcome,
nd that more intensive lowering of LDL-C levels may be
ssociated with regression of atheromatous plaque (1).
See page 2736
In this issue of the Journal, Bayturan et al. (2) focus on the
hallenging question of plaque progression in patients with
hat is currently accepted as well-treated LDL-C, an
n-treatment LDL-C level of 70 mg/dl. Using serial
VUS measurements, they report clinical predictors of
rogression (5% increase in percent plaque volume as
ercent of segmental arterial volume) in 951 such patients
tudied in 7 different clinical trials. Given the possible
uestions regarding conclusions based on groups of patients
reated with very different pharmacotherapeutic agents, the
ndings in the 200 (21%) progressors compared with the
51 (79%) nonprogressors are nonetheless hypothesis gen-
rating and, indeed, in keeping with clinical instinct and
revious knowledge. Disease progression despite low
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, Lady Davis Carmel Medicala
enter, and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel
nstitute of Technology, Haifa, Israel.DL-C levels was, not surprisingly, independently associ-
ted with the presence of diabetes mellitus, higher systolic
lood pressure, smaller increase in HDL-C, and a smaller
ecrease in apolipoprotein B (apoB) levels. Smaller baseline
bsolute and percent atheroma volume predicted progres-
ion but was more difficult to explain, perhaps a mathemat-
cal finding when percent change rather than absolute
hange was reported. Assessing progression solely as a
ercentage of baseline plaque volume may not be the ideal
orrelate for late outcome events.
The findings redefine and confirm therapeutic targets
eyond LDL-C lowering on which to focus if we are to halt
rogression of atheromatous disease. However, 2 major
ssues need to be considered. First, we currently do not have
clear treatment strategy for these targets. Aggressive
lycemic management in diabetic patients is being reevalu-
ted after the ACCORD (Action to Control Cardiovascular
isk in Diabetes) study, the ADVANCE (Action in Dia-
etes and Vascular Disease: Preterax and Diamicron MR
ontrolled Evaluation) study, and the VA Diabetes Trial
3), and the target management level may need tailoring on
n individual basis (4). It is quite likely that the exact
harmacotherapeutic agent may be crucial with regard to
linical outcome. In the PERISCOPE (Pioglitazone Effect
n Regression of Intravascular Sonographic Coronary Ob-
truction Prospective Evaluation) study (5), pioglitazone
as associated with a greater than expected change in
theroma volume. With regard to HDL-C, we do not yet
ave an effective treatment for raising HDL-C that has clear
enefit on clinical outcome. Niacin treatment needs more
efinitive outcome data, although promising (6), and the
rst major trial of a cholesteryl ester transfer protein
nhibitor to raise HDL-C was associated with side effects
nd increased mortality (7). New drugs acting on apoB and
ther lipid fractions all need to be tested mechanistically as
ell as in terms of clinical outcome events.
Second, and beyond the provision of optimal therapy for
ccepted risk factors, is another not less important un-
nown—the relation between plaque volume, plaque char-
cteristics, and clinical outcome events. Although plaques
hat rupture and cause an acute event are almost always large
8,9), specific plaque characteristics may have greater pre-
ictive value. Recent evidence from studies using VH-IVUS
hows that characteristics of plaque are related to the major
isk factors diabetes, hypertension, and serum LDL-C and
DL-C levels (10), and that the ratio of necrotic core to
ense calcium seems to correlate with LDL-C and the total
holesterol/HDL-C ratio (11). In patients with stable angina
ectoris, serial coronary VH-IVUS studies after statin therapy
howed that total plaque volume and fibrofatty plaque volume
ecreased, and fibrous plaque volume increased (12). There
ay be drug differences: fibrofatty plaque decreased with
itavastatin in correlation with LDL-C levels but not with
torvastatin (13). It appears that plaque characteristics by IVUS
nd VH-IVUS may indeed relate to outcome events. In the
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Progression Toward Regression June 15, 2010:2743–4ROSPECT (Providing Regional Observations to Study Pre-
ictors of Events in the Coronary Tree) trial, the combination
f a large nonculprit plaque burden, small luminal area (4
m2) and large necrotic core without visible cap (combination
ound in 15% of this acute coronary syndrome population) was
ssociated with an almost 10-fold increase in major adverse
ardiovascular events (14). We need more in vivo information
f we are to piece together the missing links in the chain
etween plaque volume and a clinically relevant event. Deter-
inants of plaque volume may be different from those trigger-
ng an acute event. Indeed, although, in the present study,
hanges in C-reactive protein or LDL-C itself did not predict
laque progression, the clinical arena suggests that these may
e important in predicting, determining, or triggering clinical
vents (15–17).
Notwithstanding the limitations in our knowledge, the
resent paper, as a form of “GPS,” suggests that we appear
o be at least somewhat on track in our fight to halt and
erhaps reverse the pathology and progression of athero-
clerotic vascular disease. By focusing on the 20% who
rogress “beyond LDL-C lowering,” we may better improve
herapeutic strategies for all.
eprint requests and correspondence: Dr. Basil S. Lewis, De-
artment of Cardiovascular Medicine, The Heart Hospital at Lady
avis Carmel Medical Center, 7 Michal Street, Haifa 34362,
srael. E-mail: lewis@tx.technion.ac.il.
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